Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined immunization of COVID-19 inactivated vaccine with PPV23 or IIV4
ChiCTR2100046227Phase 4Recruiting
- Sponsor
- Hubei Provincial Center for Disease Control and Prevention
- Start
- May 2021
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of 23-valent pneumococcal polysaccharide vaccine and quadrivalent influenza vaccine in coronavirus disease 2019 (COVID-19), pneumococcal disease and influenza (3 arms), sponsored by Hubei Provincial Center for Disease Control and Prevention. Primary endpoints: Antibody positive rate, Seroconversion rate and 1 more. Started May 2021; status: recruiting.
02
Drugs
23-valent pneumococcal polysaccharide vaccinequadrivalent influenza vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)pneumococcal diseaseinfluenza
Beyond the preview
Go deeper on ChiCTR2100046227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046227.